# Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease

> **NCT00287170** · PHASE1,PHASE2 · COMPLETED · sponsor: **Teva GTC** · enrollment: 15 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Delayed Release 6MP or Calcitriol vs. Purinethol

## Key facts

- **NCT ID:** NCT00287170
- **Lead sponsor:** Teva GTC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2008-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287170, "Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00287170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*